Sugi Predict

Sugi Predict / Compounds / SCHEMBL7897285

SCHEMBL7897285

SCHEMBL7897285

c1cncc(C2CNC2)c1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 1/20 0.60
▸ CHRNB2 P17787 11/20 0.55
▸ CHRNA4 P43681 11/20 0.55
▸ CHRNA7 P36544 6/20 0.50
▸ CYP2A6 P11509 3/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ CYP2D6 P10635 2/20 0.49
▸ CYP2C19 P33261 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CHRNB4 P30926 3/20 0.47
▸ CHRNA3 P32297 3/20 0.47
▸ KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30098549 1.00 CYP11B2 (0.60) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Hydrochloric Acid SCHEMBL1739285 0.98 CYP11B2 (0.58) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Hydrochloric Acid SCHEMBL21641116 0.98 CYP11B2 (0.58) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL5939874 0.89 CYP11B2 (0.53) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL5937528 0.89 CYP11B2 (0.53) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Hydrochloric Acid SCHEMBL30574215 0.87 CYP11B2 (0.51) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL717702 0.85 CYP11B2 (0.62) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
SCHEMBL19566656 0.85 CYP11B2 (0.62) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6
Trifluoroacetic Acid SCHEMBL31126136 0.84 KDM4E (0.48) CYP11B2CHRNB2CHRNA4CHRNA7CHRNB4
Hydrochloric Acid SCHEMBL2091699 0.83 CYP11B2 (0.61) CYP11B2CHRNB2CHRNA4CHRNA7CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220127254-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER MERCK PATENT GMBH (DE) 2022-04-28 — — US claimed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
WO-2024238598-A2 STAT DEGRADERS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2024-11-21 — — WO disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
EP-3724194-B1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION THERAPEUTICS AS (DK) 2023-12-27 — — EP disclosed
CN-111712502-B Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors 联合疗法公司 2023-10-27 — — CN disclosed
WO-2023192960-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-10-05 — — WO disclosed
US-20230265094-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2023-08-24 — — US disclosed
WO-2023134266-A1 2-PIPERIDYL OR 2-PYRAZOLYL SUBSTITUTED PYRIMIDINE COMPOUND SERVING AS EGFR INHIBITOR 苏州浦合医药科技有限公司 2023-07-20 — — WO disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
US-20140088081-A1 Amino-Heterocyclic Compounds PFIZER INC. (US) 2014-03-27 — — US disclosed
WO-2013170113-A1 NAMPT INHIBITORS ABBVIE INC. (US) 2013-11-14 — — WO disclosed
EP-2389382-B1 Amino-heterocyclic compounds used as pde9 inhibitors PFIZER (US) 2013-06-05 — — EP disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 — — US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 — — US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 — — US disclosed
WO-2010084438-A1 AMINO-HETEROCYCLIC COMPOUNDS USED AS PDE9 INHIBITORS PFIZER INC. (US) 2010-07-29 — — WO disclosed
US-4163856-A Azetidine compounds and process for production PHILIP MORRIS INCORPORATED (US) 1979-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329777-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A CYP11B2 603/4885CHRNB2 170/4885CHRNA4 161/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A CYP11B2 603/4885CHRNB2 170/4885CHRNA4 161/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A CYP11B2 1038/4885CHRNB2 4847/4885CHRNA4 4788/4885
US-20230265094-A1 RIPK1 INHIBITORS AND METHODS OF USE RIPK1, RIPK2, RIPK3 CYP11B2 2740/4885CHRNB2 4545/4885CHRNA4 4754/4885
US-20220127254-A1 INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER KIT, TNNI3K, CILK1 CYP11B2 734/4885CHRNB2 2331/4885CHRNA4 2299/4885
US-20140088081-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A CYP11B2 603/4885CHRNB2 170/4885CHRNA4 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.